AZD4635 (Synonyms: HTL-1071, Imaradenant) |
Catalog No.GC19049 |
AZD4635 (HTL1071) is a potent, selective and orally active adenosine A2A receptor (A2AR) antagonist. AZD4635 binds to human A2AR with a Ki of 1.7 nM and shows >30-fold selectivity over other adenosine receptors.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1321514-06-0
Sample solution is provided at 25 µL, 10mM.
AZD4635 is a potent and selective, orally available adenosine A2A receptor (A2AR) antagonist. AZD4635 binds to human A2AR with a Ki of 1.7 nM and with > 30-fold selectivity over other adenosine receptors[1].
In the presence of 0.1, 1 and 10 μM adenosine, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM, respectively[1].
References:
[1]. Alexandra Borodovsky, et al. Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5580.
Average Rating: 5
(Based on Reviews and 17 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *